| Drug Name: | Ticlopidine (55142-85-3) |
|---|---|
| PubChem ID: | 5472 |
| SMILES: | C1CN(CC2=C1SC=C2)CC3=CC=CC=C3Cl |
| InchiKey: | PHWBOXQYWZNQIN-UHFFFAOYSA-N |
| Therapeutic Category: | Cardiovascular Agents, Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 Enzyme Inhibitors, Enzyme Inhibitors, Fibrin Modulating Agents, Fibrinolytic Agents, Hematologic Agents, Neurotransmitter Agents, Platelet Aggregation Inhibitors, Purinergic Agents, Purinergic Antagonists, Purinergic P2 Receptor Antagonists, Purinergic P2Y Receptor Antagonists |
| Molecular Weight (dalton) | : | 263.793 |
| LogP | : | 3.9598 |
| Ring Count | : | 2 |
| Hydrogen Bond Acceptor Count | : | 2 |
| Hydrogen Bond Donor Count | : | 0 |
| Total Polar Surface Area | : | 3.24 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|---|---|---|---|
| Carbamazepine (298-46-4) | Ataxia | Synergistic | uncertain | Ticlopidine-carbamazepine interaction in a coronary stent patient |
| Phenytoin (57-41-0) | Somnolence | Synergistic | The metabolism of phenytoin to 5-(4-hydroxyphenyl)-5-phenylhydantoin (HPPH) by the cytochrome P450 isoenzyme CYP2C19, and to a lesser extent by CYP2C9, in the liver is inhibited by ticlopidine. Further metabolism of HPPH to dihydroxylated products is mediated mainly by CYP2C19 and this may also be inhibited by ticlopidine | Ticlopidine impairs phenytoin clearance: a case report |
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category